Home » Newsletters » BioWorld Science

BioWorld Science

July 20, 1998

View Archived Issues

One-year trial shows efficacy of lamivudine for treatment for chronic hepatitis B

LY-117018 is fully protective during the later slow phase of bone loss

Selective COX-1 and COX-2 blockade as novel anticancer approach

Company profile: Esperion Therapeutics

OSI receives patent protection for its gene transcription-regulating drugs

Alza: Q1 1998 highlights

Gelatinase inhibitors developed at Sankyo useful for cancer

Paracelsian and Southern Research Institute to develop new anticancer drugs

FDA priority review status granted to Panretin Gel for AIDS-related KS

PathoGenesis completes patient enrollment in phase II TOBI trial

Japanese team presents new antitumor anthracyclines

Solvay describes motilin agonists related to erythromycin

Novel compounds described by Japan Energy for lipid disorders

Antibacterial agent of microbial origin discovered by Sankyo

Sankyo presents new antifungal agents for Candida infections

Medarex begins clinical trials of Bispecific antibody for cancer

FDA grants second orphan drug designation for ImmTher

Celgene cleared to market Thalomid in U.S.

JTV-519 protects heart during prolonged ischemia

FR-167653 attenuates ischemia-reperfusion injury to the lung in rat model

Schering-Plough acquires exclusive worldwide rights to oral ribavirin for HCV

Human vaccination study demonstrates potential of oral and nasal MaxVax

New treatment for male hypogonadism introduced in Germany

Chemokine receptor antagonist NSC-651016 shows potent anti-HIV activity in preclinical studies

PNU-109291, a selective 5-HT1D agonist and potent antimigraine agent

Sanwa Kagaku licenses Bayer antidiabetic agent for Japanese development

FDA accepts license applications for CroTAb

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...